Source: yahoo_news
Source ID: yahoo:a64f0ba387af5ba4cd3ea77e3dd1d98a:RXRX
URL: https://finance.yahoo.com/healthcare/articles/recursion-announces-200-million-oversubscribed-122200936.html?.tsrc=rss
Symbol: (RXRX)
Published: 2026-10-15 08:22:00 EDT
Time precision: minute
Title: Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital Management and other prominent healthcare specialists and mutual funds invest $200 million in RecursionREC-4881 (MEK1/2 inhibitor) Phase 1b/2 Data Update: Deep, durable polyp burden reductions reproduced in the expanded adult FAP population (18+), with a 47% median reduction after 12 weeks of treatment and 85% of patients maintaining reductions below baseline after 12 weeks o